Search Within

Andriy Derkach

Formats
  1. Meeting Abstract (104)
  2. Journal Article (56)
  3. Research Letter (11)
  4. Correspondence (3)
Groups
  1. Biostatistics Service (174)
  2. Epidemiology and Biostatistics (174)
  3. Population Sciences Research Program (174)
  4. Department of Medicine (160)
  5. Hematologic Malignancies, Division of (159)
  6. Center for Hematologic Malignancies (153)

More Groups

People
  1. Urvi Shah (80)
  2. Malin Hultcrantz (79)
  3. Alexander Lesokhin (78)
  4. Carlyn Rose Tan (71)
  5. Sham Mailankody (71)
  6. Hani Hassoun (70)

More People

Years
  1. 2025 (10)
  2. 2024 (47)
  3. 2023 (44)
  4. 2022 (35)
  5. 2021 (22)
  6. 2020 (16)
Publications
  1. Blood (75)
  2. Clinical Lymphoma, Myeloma and Leukemia (21)
  3. Journal of Clinical Oncology (14)
  4. Blood Advances (10)
  5. Leukemia and Lymphoma (6)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (85)
  2. Elsevier Inc. (24)
  3. American Society of Clinical Oncology (14)
  4. Nature Publishing Group (12)
  5. American Association for Cancer Research (8)
  6. Taylor & Francis Group (6)

More Publishers

Results (174)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
    Journal Article

    Burton, H.; Boussi, L.; Nemirovsky, D.; Derkach, A.; Ciervo, J.; Famulare, C.; Chin, K. K.; Valtis, Y.; Yisraeli Salman, M.; Patel, K.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Investigating disparities in prescription drug use among Mexican Americans and non-Hispanic Whites
    Journal Article

    Monroy-Iglesias, M. J.; Zuckerman, G.; Wang, P.; Derkach, A.; O’Connell, K.; Lund, J. L.; Du, M.; Bhimani, J.; Giovannucci, E. L.; Schwartz, T. A.; more...
    Journal of Racial and Ethnic Health Disparities (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
    Journal Article

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
    Journal Article

    Galera, P.; Dilip, D.; Derkach, A.; Chan, A.; Zhang, Y.; Persaud, S.; Mishra, T.; Kramer, K.; Kathpalia, M.; Liu, Y.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival
    Journal Article

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save